Table 4 Clinical features of ENKTL-Breast cases acquired from the present study and literature review

Number of cases

8 (P: 3; S: 5)

7 (P: 4; S: 3)

15 (P: 7; S:8)

Median age (range) (year)

46 (26–63)

38 (20–47)

41 (20–63)

Origin (Asian/non-Asian)

8/0

1/3

9/3

Initial presented with breast mass (yes/no)

8/0

6/1

14/1

B symptoms (yes/no)

7/1

3/1

10/2

Ann Arbor stage (I/II vs III/IV)

P: 3/0; S: 0/4

P: 2/0; S: 0/3

P: 5/0; S: 0/7

Immunophenotype CD56 (positive/negative)

P: 2/1; S: 4/1

P: 2/0; S: 2/1

P: 4/1; S: 6/2

EBER (positive/negative)

8/0

6/1

14/1

TR gene rearrangement (monoclonal/polyclonal)

P: 2/0; S: 1/4

P: 1/2; S: 0/1

P: 3/2; S: 1/5

Concomitant diseases (yes/no)

P: 2/0; S: 1/4

P: 3/0; S: 0/3

P: 5/0; S: 1/7

Outcome(died/alive)

6/0

3/1

9/1

Median survival (range) (month)

6 (2–11)

5 (1–18)

5 (1–18)